Bevacizumab gives a boost to chemotherapeutics in mCRC

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1603, 2007-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Picoplatin promising as treatment for both mCRC and HRPC

Inpharma, Vol. 1, Iss. 1662, 2008-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

KRAS status predicts response to cetuximab in mCRC

Inpharma, Vol. 1, Iss. 1641, 2008-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Cetuximab launched for mCRC, approved for SCCHN.

Inpharma, Vol. 1, Iss. 1663, 2008-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Cetuximab extends survival in patients with mCRC

Inpharma, Vol. 1, Iss. 1657, 2008-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Bevacizumab "best value for money" in MCRC . . .

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 666, 2012-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite